News

Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the “CDRX” ticker symbol. As part of the merger, Candid has secured more

CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform. The asset specifically targets resistant mutations

The recommendation applies to children aged two to 11 years experiencing moderate-to-severe CSU who do not respond adequately to histamine-1 antihistamines and are naïve to anti-immunoglobulin E (IgE) therapy.

This makes Palynziq the only enzyme substitution therapy that received approval to reduce blood phenylalanine (Phe) concentrations in individuals with PKU. The approval follows data from PEGASUS, a

The acquisition will expand the company’s speciality pharmaceutical platform into severe infectious diseases. Completion is expected in the first quarter of fiscal 2026, subject to customary conditions. The

FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes

The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are

Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered

The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong). The company is headed by CEO and board director Gregory Oakes,